New therapeutic alternatives for severe sepsis in the critical patient. A review;Nuevas alternativas terapéuticas para la sepsisgrave en el paciente crítico. Revisión

Medicina Intensiva

Volumn 35, Issue 4, 2011, Pages 236-245

  Loza Vazquez A ^a   Leon Gil C ^a   Leon Regidor A ^b  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL GENERAL DE CATALUNYA   (Spain)

Author keywords

Critically ill patient; Sepsis

Indexed keywords

CLINICAL PRACTICE; CRITICALLY ILL PATIENT; EVIDENCE BASED MEDICINE; HUMAN; PEER REVIEW; PRACTICE GUIDELINE; SEPSIS; SHORT SURVEY; SYSTEMATIC REVIEW;

COMBINED MODALITY THERAPY; CONSENSUS; CRITICAL CARE; HEALTH PROMOTION; HUMANS; MULTIPLE ORGAN FAILURE; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEPSIS; SOCIETIES, MEDICAL; THERAPIES, INVESTIGATIONAL;

EID: 79955721898     PISSN: 02105691     EISSN: 15786749     Source Type: Journal    
DOI: 10.1016/j.medin.2010.10.002     Document Type: Short Survey

References (48)

1. Dellinger R.P., Carlet J.M., Masur H., Gerlach H., Calandra T., Cohen J., et al. Surviving Sepsis Campaign. Guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004, 32:858-873.
2. Dellinger R.P., Levy M.M., Carlet J.M., Bion J., Parker M.M., Jaeschke R., et al. International guidelines for management of severe sepsis and septic shock. Crit Care Med. 2008, 36:1394-1396.
3. León C., García-Castrillo L., Moya M., Artigas A., Borges M., Candel F.J., et al. Documento de consenso (Semes-Semicyuc). Recomendaciones del manejo diagnóstico-terapéutico inicial y multidisciplinario de la sepsis grave en los servicios de urgencias hospitalarios. Med Intensiva. 2007, 31:375-387.
4. Kumar A., Daniel R., Kenneth W., Bruce L., Parrillo J.E., Satendra S., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006, 34:1589-1596.
5. Rivers E., Nguyen B., Havstad S., Ressler J., Muzzin A., Knoblich B., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001, 345:1368-1377.
6. Ferrer R., Artigas A., Levy M.M., Blanco J., González G., Garnacho-Montero J., et al. Improvement in Process of Care and Outcome after a Multicenter Severe Sepsis Educational Program in Spain. JAMA. 2008, 299:2294-2303.
7. Iñigo J., Sendra J.M., Díaz R., Bouza C., Sarría- Santamera A. Epidemiología y costes de la sepsis grave en Madrid. Estudio de altas hospitalarias. Med Intensiva. 2006, 30:197-203.
8. Esteban A., Frutos-Vivar F., Ferguson N.D., Peñuelas O., Lorente J.A., Gordo F., et al. Sepsis incidence and outcome: Contrasting the intensive care unit with the hospital ward. Crit Care Med. 2007, 35:1284-1289.
9. De Miguel-Yanes J.M., Andueza-Lillo J.A., González-Ramallo V.J., Pastor L., Muñoz J. Failure tu implement evidence-based clinical guidelines for sepsis at the ED. Am J Emerg Med. 2006, 24:553-559.
10. Carlbom D.J., Rubenfeld G.D. Barriers to implementing protocol-based sepsis resuscitation in the emergency department. Results of a national survey. Crit Care Med. 2007, 35:2525-2532.
11. Shorr A.F., Micek S.T., Jackson W.L., Kollef M.H. Economic implications of an evidence-based sepsis protocol: Can we improve outcomes and lower costs?. Crit Care Med. 2007, 35:1257-1262.
12. Ferrer R., Artigas A., Suarez D., Palencia E., Levy M.M., Arenzana A., et al. Effectiveness of treatments for severe sepsis: a prospective multicenter observational study. Am J Respir Crit Care Med. 2009, 180:861-866.
13. Annane D., Vignon P., Renault A., Bollard P.E., Charpentier C., Martin C., et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet. 2007, 370:676-684. CATS Study Group.
14. De Backer D., Biston P., Devriendt J., Madl C., Chochrad D., Aldecoa C., et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010, 362:779-789.
15. McLean AS. Levosimendan versus dobutamine in shock patients. ClinicalTrials.gov Identifier: NCT00093301.
16. Latour-Pérez J, García MA. Dosis óptima de diálisis en pacientes con daño renal agudo. Una revisión crítica de la literatura. Revista Electrónica de Medicina Intensiva. Artículo especial n° 104. REMI 2009; 9(6):A104. Disponible en: http://remi.uninet.edu/2009/06/REMIA104.html.
17. Cruz D.N., Antonelli M., Fumagalli R., Foltran F., Brienza N., Donati A., et al. Early use of polymyxin B hemoperfusionin abdominal septic shock. The EUPHAS Randomized Controlled Trial. JAMA. 2009, 301:2445-2452.
18. Busund R., Koukline V., Utrobin U., Nedashkovsky E. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med. 2002, 28:1434-1439.
19. Livigni S. COMPACT - Combining Plasma-filtration and Adsorption Clinical Trial. ClinicalTrials.gov Identifier: NCT00332371.
20. Griesdale D., De Souza R.J., Van Dam R.M., Heyland D.K., Cook D.J., Malhotra A., et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ. 2009, 180:821-827.
21. Wiener R.S., Wiener D.C., Larson R.J. Benefits and risks of tight glucose control in critically ill adults a meta-analysis. JAMA. 2008, 300:933-944.
22. Anticoagulant therapy in severe sepsis. American Thoracic Society CAT; 2005.
23. Eid A., Wiedermann C.J., Kinasewitz G.T. Early administration of high-dose antithrombin in severe sepsis: single center results from the KyberSept-Trial. Anesth Analg. 2008, 107:1633-1638.
24. Abraham A., Reinhart K., Opal S., Demeyer I., Doig C., López A., et al. Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis: A Randomized Controlled Trial. JAMA. 2003, 290:238-247.
25. Martí-Carvajal AJ, Salanti G, Cardona AF-Zorrilla. Proteína C activada recombinante para la sepsis grave en humanos Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD004388. DOI: 10.1002/14651858.CD004388.
26. Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock. ClinicalTrials.gov Identifier: NCT00604214.
27. Misset B, Martin C, Cariou A, Carlet J, Brun Buisson C, Annane D. Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHS). ClinicalTrials.gov: NCT00625209.
28. Sprung C.L., Annane D., Keh D., Moreno R., Singer M., Freivogel K., et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008, 358:111-124.
29. Annane D., Bellissant E., Bollaert P.E., Briegel J., Confalonieri M., De Gaudio R., et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults. A systematic review. JAMA. 2009, 301:2362-2375.
30. The use of nitric oxide in acute respiratory distress syndrome. Accession number: 32007000487. Centre for Reviews and Diseminación. DARE 07.
31. Trzeciak S. Randomized Trial of Inhaled Nitric Oxide to Augment Tissue Perfusion in Sepsis. ClinicalTrials.gov: NCT00608322.
32. Kopterides P., Falagas M.E. Statins for sepsis: a critical and updated review. Clin Microbiol Infect. 2009, 15:325-334.
33. Schenk P. Simvastatin in Patients With Septic Shock. ClinicalTrials.gov: NCT00450840.
34. Truwit J. Statins for Acutely Injured Lungs From Sepsis (SAILS). ClinicalTrials.gov: NCT00979121.
35. Laupland K.B., Kirkpatrick A.W., Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: A systematic Review and meta-analysis. Crit Care Med. 2007, 35:2686-2692.
36. Gómez-Tello V. Inmunoglobulinas en el tratamiento de la sepsis. REMI. 2008, 8:1186.
37. Massey E, Paulus U, Doree C, Stanworth S. Transfusiones de granulocitos para la prevención de infecciones en pacientes con neutropenia o disfunción de los neutrófilos. La Biblioteca Cochrane Plus 2009, Número 3,.
38. Smith T.J., Khatcheressian J., Lyman G.H., Ozer H., Armitage J.O., Balducci L., et al. Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. National Guideline Clearinghouse; 2006.
39. Wang H., Ward M.F., Andrew E., Sama E. Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock. 2009, 32:348-357.
40. Angstwurm M., Engelmann L., Zimmerman T., Lehmann C., Spes C.H., Abel P., et al. Selenium in Intensive Care (SIC): Results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock. Crit Care Med. 2007, 35:118-126.
41. Schiller F. Placebo Controlled Trial of Sodium Selenite and Procalcitonin Guided Antimicrobial Therapy in Severe Sepsis (SISPCT). ClinicalTrials.gov: NCT00832039.
42. Pontes-Arruda A. The Effects of Eicosapentaenoic Acid (EPA), Gamma-Linolenic Acid (GLA) and Antioxidants in the Treatment. ClinicalTrials.gov: NCT00329680.
43. Weil B.R., Markel T.A., Herrmann J.L., Abarbanell A.M., Kelly M.L., Meldrum D.R. Stem cells in sepsis. Ann Surg. 2009, 250:19-27.
44. Würfel M.M. Genetic insights into sepsis: what have we learned and how will it help?. Curr Pharm Des. 2008, 14:1900-1911.
45. Wong HC. Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome. ClinicalTrials.gov: NCT00879606.
46. Guntupalli KK. Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis. ClinicalTrials.gov: NCT00630656.
47. Said S. Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis. ClinicalTrials.gov: NCT00004494.
48. Takeda Global Research & Development. Efficacy & Safety of Resatorvid in Adults With Severe Sepsis. ClinicalTrials.gov: NCT00143611.